Cardiovascular MR to assess myocardial viability in chronic ischaemic LV dysfunction

Heart

Volumn 91, Issue 10, 2005, Pages 1359-1365

  Kaandorp, T A M ^a   Lamb, H J ^a   Van Der Wall, E E ^a   De Roos, A ^a   Bax, J J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DOBUTAMINE; CARDIOTONIC AGENT; CONTRAST MEDIUM; DIAGNOSTIC AGENT;

CARDIOMYOPATHY; CHRONIC DISEASE; CONTRAST ENHANCEMENT; HEART EJECTION FRACTION; HEART FUNCTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE WALL; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; STUNNED HEART MUSCLE; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING ORGAN SYSTEMS; CONVALESCENCE; HEART LEFT VENTRICLE FUNCTION; MAGNETIC RESONANCE ANGIOGRAPHY; METHODOLOGY;

CARDIOTONIC AGENTS; CONTRAST MEDIA; DOBUTAMINE; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MYOCARDIAL ISCHEMIA; RECOVERY OF FUNCTION; TISSUE SURVIVAL; VENTRICULAR DYSFUNCTION, LEFT;

EID: 25144464543     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2003.025353     Document Type: Review

References (20)

1. American Heart Association Heart disease and stroke statistics, 2005 update. Dallas, Texas: American Heart Association, 2005.
2. Rahimtooia SH. The hibernating myocardium. Am Heart J 1989;117:211-21. Key reference emphasising the concept of myocardial hibernation.
3. Vanoverschelde JL, Wijns W, Depre C, et al. Mechanisms of chronic regional postischemic dysfunction in humans. New insights from the study of noninfarcted collateral-dependent myocardium. Circulation 1993;87:1513-23. Landmark paper on the concept of repetitive stunning.
4. Box JJ, Van Der Wall EE, Harbinson M. Radionuclide techniques for the assessment of myocardial viability and hibernation. Heart 2004;90(suppl 5):v26-33.
5. Baer FM, Voth E, Schneider CA, et al. Comparison of low-dose dobutamine-gradient-echo magnetic resonance imaging and positron emission tomography with [18F]fluorodeoxyglucose in patients with chronic coronary artery disease. A functional and morphological approach to the detection of residual myocardial viability. Circulation 1995;91:1006-15.
6. Baer FM, Theissen P, Schneider CA, et al. Dobutamine magnetic resonance imaging predicts contractile recovery of chronically dysfunctional myocardium after successful revascularization. J Am Coll Cardiol 1998;31:1040-8. Study illustrating the value of low dose dobutamine CMR to predict functional recovery post-revascularisation.
7. John AS, Dreyfus GD, Pennell DJ. Images in cardiovascular medicine. Reversible wall thinning in hibernation predicted by cardiovascular magnetic resonance. Circulation 2005;111:e24-25.
8. Kim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 1999;100:1992-2002. Study demonstrating the perfect relation between contrast enhanced CMR to detect scar tissue in comparison to histology.
9. Klein C, Nekolla SG, Bengel FM, et al. Assessment of myocardial viability with contrast-enhanced magnetic resonance imaging: comparison with positron emission tomography. Circulation 2002;105:162-7. Head to head comparison between contrast enhanced CMR and positron emission tomography and F18- fluorodeoxyglucose.
10. Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000;343:1445-53. Landmark paper on the prediction of functional recovery after revascularisation using contrast enhanced CMR.
11. Wellnhofer E, Olariu A, Klein C, et al. Magnetic resonance low-dose dobutamine test is superior to SCAR quantification for the prediction of functional recovery. Circulation 2004;109:2172-4.
12. Kaandorp TA, Box JJ, Schuijf JD, et al. Head-to-head comparison between contrast-enhanced magnetic resonance imaging and dobutamine magnetic resonance imaging in men with ischemic cardiomyopathy. Am J Cardiol 2004;93:1461-4.
13. Wellenberg JJ, Doornbos J, Versteegh MI, et al. Accurate quantitation of regurgitant volume with MRI in patients selected for mitral valve repair. Eur J Cardiothorac Surg 2005;27:462-6.
14. Schmidt M, Voth E, Schneider CA, et al. F-18-FDG uptake is a reliable predictor of functional recovery of akinetic but viable infarct regions as defined by magnetic resonance imaging before and after revascularization. Magn Reson Imaging 2004;22:229-36.
15. Baer FM, Theissen P, Crnac J, et al. Head to head comparison of dobutamine-transoesophageal echocardiography and dobutamine-magnetic resonance imaging for the prediction of left ventricular functional recovery in patients with chronic coronary artery disease. Eur Heart J 2000;21:981-91.
16. Gunning MG, Anagnostopoulos C, Knight CJ, et al. Comparison of 201Tl, 99mTc-tetrofosmin, and dobutamine magnetic resonance imaging for identifying hibernating myocardium. Circulation 1998;98:1869-74.
17. Sayad DE, Willett DL, Hundley WG, et al. Dobutamine magnetic resonance imaging with myocardial tagging quantitatively predicts improvement in regional function after revascularization. Am J Cardiol 1998;82:1149-51, A10.
18. Sandstede JJ, Bertsch G, Beer M, et al. Detection of myocardial viability by low-dose dobutamine cine MR imaging. Magn Reson Imaging 1999;17:1437-43.
19. Trent RJ, Waiter GD, Hillis GS, et al. Dobutamine magnetic resonance imaging as a predictor of myocardial functional recovery after revascularisation. Heart 2000;83:40-6.
20. Selvanayagam JB, Kardos A, Francis JM, et al. Value of delayed-enhancement cardiovascular magnetic resonance imaging in predicting myocardial viability after surgical revascularization. Circulation 2004;110:1535-41.